Curetis Overview
- Founded
-
2007
- Status
-
Out of Business
- Employees
-
79
- Latest Deal Type
-
Liquidation
- Financing Rounds
-
11
- Investments
-
3
Curetis General Information
Description
Curetis NV is a commercial-stage molecular diagnostics company focused on rapid infectious disease testing for hospitalized patients. The company has developed Unyvero molecular diagnostic solution for comprehensive infectious disease testing.
Contact Information
Primary Industry
Diagnostic Equipment
Former Stock Listing
CUREA
Primary Office
- Max-Eyth-Straße 42
- 71088 Holzgerlingen
- Germany
Curetis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Curetis Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Curetis NV is a commercial-stage molecular diagnostics company focused on rapid infectious disease testing for hospitali
Diagnostic Equipment
Holzgerlingen, Germany
79
As of 2019
00000
000000000000
000000
ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolor
0000000000 000000000
Seoul, South Korea
000
As of 0000
000.00
0000
0000-00-00
00000000
000.00
00 000
usmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exer
0000000000 000000000
Lexington, MA
000
As of 0000
00000
00000000000
00000
Add Comparison
Curetis Competitors (7)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| QuantaMatrix | Formerly VC-backed | Seoul, South Korea | 000 | 000.00 | 00000000 | 000.00 |
| 00 0000000000 | Formerly VC-backed | Lexington, MA | 000 | 00000 | 00000000000 | 00000 |
| 000000000000 | Private Equity-Backed | Puteaux, France | 000 | 000.00 | 000000000000 | |
| 0000000000 0000000 | Corporation | Tucson, AZ | 000 | 000.00 | 0000000000 | 000.00 |
| 000000000 | Formerly VC-backed | Mechelen, Belgium | 000 | 00000 | 000000000 | 00000 |
Curetis Patents
Curetis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3216873-A1 | Combination of structural variations and single nucleotide changes in one statistical model for improved therapy selection | Pending | 08-Mar-2016 | 0000000000 | 0 |
| AU-2016299328-A1 | Genetic testing for predicting resistance of stenotrophomonas species against antimicrobial agents | Abandoned | 29-Jul-2015 | 000000000 | |
| CA-2991671-A1 | Genetic testing for predicting resistance of stenotrophomonas species against antimicrobial agents | Pending | 29-Jul-2015 | 000000000 | |
| EP-3329009-A1 | Genetic testing for predicting resistance of stenotrophomonas species against antimicrobial agents | Withdrawn | 29-Jul-2015 | 000000000 | |
| US-20180216167-A1 | Genetic testing for predicting resistance of stenotrophomonas species against antimicrobial agents | Abandoned | 29-Jul-2015 | C12Q1/689 | 00 |
Curetis Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Curetis Investments (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 0000 | 13-Dec-2016 | 000000000 | 00.000 | Buildings and Property | 000000 00 |
| 0000 00000000 | 07-Sep-2016 | 000000000 | Buildings and Property | 000000 00 | |
| Ares Genetics | Seed Round | Other Pharmaceuticals and Biotechnology |